Form 4: Cytokinetics EVP, Chief Commercial Officer Andrew Callos Sells Shares

Andrew Callos, EVP, Chief Commercial Officer of Cytokinetics Inc, sold 26,771 shares of common stock on March 13, 2025, at a price of $43.62 per share.

Summary

• On March 13, 2025, Andrew Callos, the EVP, Chief Commercial Officer of Cytokinetics Inc, sold 26,771 shares of the company's common stock.
• The sale was executed at a price of $43.62 per share.
• Following the transaction, Mr. Callos directly owns 37,663 shares of Cytokinetics Inc.

Sentiment

Score: 5

Explanation: This is a neutral event. It's a routine disclosure of an insider stock sale. The impact on sentiment depends on the broader context and the reasons behind the sale, which are not disclosed here.

Industry Context

This is a standard SEC Form 4 filing, which is required when a company insider buys or sells shares of their own company. It provides transparency into the transactions of company executives and directors.

Stakeholder Impact

• The sale of shares by a company executive could be perceived negatively by some shareholders, as it might suggest a lack of confidence in the company's future prospects, although this is not necessarily the case.

Key Dates